Cargando…
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma
The prognosis of esophageal cancers is poor and novel approaches are urgently needed. Despite improvements in outcomes with transtuzumab and ramucirumab, these improvements added an average of only 2 to 3 months with a median overall survival reported to be around 1 year. Comprehensive genomic seque...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5126797/ https://www.ncbi.nlm.nih.gov/pubmed/27854242 http://dx.doi.org/10.3390/jcm5110100 |